DOCSLIB.ORG

A4 Annual Report AW 070716

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A4 Annual Report AW 070716 02 Leadership In A Changing World Chairman’s Letter Dear Shareholders, When I founded Lupin over 48 years ago, the goal was simple; to manufacture and deliver quality, affordable medicines of the highest national and social priority. It has been the core principle and guiding philosophy behind everything we have undertaken and achieved over now close to five decades. This is reflected in how Lupin has expanded over the years, the markets that we have chosen to focus on and in how we have nurtured and grown them. It is also reflected in how Lupin has gone about investing in and growing our research programs to build an impressive product pipeline and in how we have created a quality driven global manufacturing organization, second to none in the pharmaceutical industry. FY 2016 saw us invest the highest ever in Research & Development to date. Today, it is clear to me that the unassuming choice that we made of being inclusive in creating relevant products that people need is what has made Lupin the global pharmaceutical powerhouse that it is. It has also been the key trigger driving Lupinytts to be creative in working together to innovate, execute and deliver efficacious products to our communities. This differentiator has ensured Lupin’s continued progression and ascendance as a global leader and a true innovator. At Lupin, success is not just about growth or performance, it has always been about doing the right thing no matter how challenging the environment; about backing our ideas and having the conviction to see them through. It is about being the transformation ourselves. That is the only thing that ensures leadership in a changing world. At Lupin, leadership is a given and numbers are just milestones on a glorious path. Dr. Desh Bandhu Gupta Founder & Chairman Lupin Limited 04 Corporate Information DIRECTORS CORPORATE SOCIAL RESPONSIBILITY COMMITTEE Dr. Desh Bandhu Gupta, Chairman Dr. Desh Bandhu Gupta, Chairman Dr. Kamal K. Sharma, Vice Chairman Dr. Kamal K. Sharma Ms. Vinita Gupta, Chief Executive Officer Mr. Nilesh Gupta Mr. Nilesh Gupta, Managing Director Dr. Vijay Kelkar Mrs. Manju D. Gupta, Executive Director Mr. Ramesh Swaminathan, RISK MANAGEMENT COMMITTEE Chief Financial Officer & Executive Director Dr. Kamal K. Sharma, Chairman Dr. Vijay Kelkar, Independent Director Ms. Vinita Gupta Mr. R. A. Shah, Independent Director Mr. Nilesh Gupta Mr. Richard Zahn, Independent Director Mr. Ramesh Swaminathan Dr. K. U. Mada, Independent Director Mr. Sunil Makharia Mr. Dileep C. Choksi, Independent Director Mr. Jean-Luc Belingard, Independent Director SENIOR MANAGEMENT TEAM Dr. Desh Bandhu Gupta, Chairman COMPANY SECRETARY Dr. Kamal K. Sharma, Vice Chairman Mr. R. V. Satam Ms. Vinita Gupta, Chief Executive Officer Mr. Nilesh Gupta, Managing Director AUDITORS Mr. Ramesh Swaminathan, Chief Financial Officer & Executive Director Deloitte Haskins & Sells LLP Mr. Shakti Chakraborty, Group President - India Region Formulations Chartered Accountants Dr. Rajender Kamboj, President - Novel Drug Discovery & Development Mr. Naresh Gupta, President - API & Global TB AUDIT COMMITTEE Mr. Divakar Kaza, President - Human Resources Dr. K. U. Mada, Chairman Mr. Alok Ghosh, President - Technical Operations Dr. Kamal K. Sharma Dr. Cyrus Karkaria, President - Biotechnology Mr. Dileep C. Choksi Mr. Sunil Makharia, President - Finance STAKEHOLDERS Mr. Debabrata Chakravorty, President - Global Sourcing RELATIONSHIP COMMITTEE & Contract Manufacturing Dr. Vijay Kelkar, Chairman Mr. Rajeev Sibal, President - India Region Formulations Dr. K. U. Mada Mr. Paul McGarty, President - Lupin Pharmaceuticals Inc., USA Dr. Sofia Mumtaz, Head - Pipeline Management & Legal NOMINATION AND Mr. Martin Mercer, President - Latin America REMUNERATION COMMITTEE Dr. Thierry Volle, President - Europe, Middle-East & Africa Dr. K. U. Mada, Chairman Dr. Fabrice Egros, President - Asia Pacific & Japan Mr. R. A. Shah Dr. Kurt Nielsen, President - Somerset, USA Mr. Richard Zahn Mr. Noriaki Tsunoda, President - Kyowa Pharmaceutical Co. Ltd., Japan STRATEGIC Website ADVISORY BOARD www.lupin.com Mr. Jean-Luc Belingard Mr. Franceso Granata E-Mail Ms. Yvonne Greenstreet [email protected] Mr. Dipak Jain CORPORATE INTERNAL AUDITORS IDENTITY NUMBER Ernst & Young LLP L24100MH1983PLC029442 KPMG REGISTERED OFFICE KEY CONTACTS Mr. Shamsher Gorawara Kalpataru Inspire, 3rd Floor Head - Corporate Communications Off Western Express Highway Email: [email protected] Santacruz (East), Mumbai - 400 055 Tel.: +91 22 6640 2323 Mr. Pradeep Bhagwat Fax: +91 22 6640 8131 General Manager, Investors’ Services CORPORATE OFFICE Email: [email protected] Laxmi Towers, ‘B’ Wing, 5th Floor Bandra Kurla Complex, Bandra (East) Mumbai - 400 051 Tel.: +91 22 6640 2222 Fax: +91 22 6640 2130 07 Taking Centerstage Awards Lupin named in the Forbes Global 2000 – Lupin in AON Best Employers India 2016 – World’s Most Powerful Public Companies amongst the Top 25 Employers Lupin named amongst the Top 3 Research Vinita Gupta, CEO & Nilesh Gupta, MD Organizations in the country – Thomson awarded the Ernst & Young Entrepreneur Reuters India Innovation Awards 2015 of the Year, India, 2015 CNBC TV18 Firm of the Year in Pharma Sector: Vinita Gupta awarded Outstanding Woman Business India Risk Management Awards – 2015 Leader of the Year – CNBC India Business Leader Awards (IBLA) FY 2015-16 Lupin named in Forbes Asia Fab 50 companies Vinita Gupta named in Forbes Asia Business 2015 for the second year running Women – Power 50 list Lupin Limited ranked 5th in Best at Investor Vinita Gupta named amongst The Most Powerful Relations by FinanceAsia Business Women 2015 by Business Today Lupin ranked 15th in the Great Places to Work Ramesh Swaminathan, CFO, Lupin Limited wins the Institute’s Best Companies to Work for in Asia Best CFO by FinanceAsia 08 The Transformation Dynamic Vice Chairman’s Letter Dear Shareholders, As I write to you, what is certain and a given is that we are living in an increasingly uncertain and volatile world leading to huge amount of complexity and ambiguity with enhanced amplitude and frequency. This poses a special challenge to the process of designing growth strategies and planning of operations. Institutions around the globe are continuously being pushed to change; if they do not proactively do so. Pharmaceutical industry being a knowledge intensive industry faces its own share of challenges. We, at Lupin, were quick to grasp this early on. We realized that spate of rapid changes demand both being adaptive and proactive. Hence, we have been investing ahead of the curve in building competencies and further sharpening our execution capabilities. We have been intuitive in our abilities to forecast changes and agile and swift in responding to them. The accent is on developing and adopting new technologies, expanding on our global footprint, building alliances, and enhancing operational excellence. We are continuously upgrading our processes to facilitate sharing of knowledge, information, and feedback seamlessly across the organization. Our network of global teams is working in tandem to serve customers and communities better in participated geographies. This Transformation Dynamic, be it in the environment or within the Company, has brought forth extraordinary opportunities of growth. We at Lupin are seizing these opportunities to create greater value. This is clearly visible in how Lupin has navigated its way through a rapidly changing world. Our growth performance, duly supported by execution excellence over the last decade, has given us deep insight and confidence to be market leaders. Confidence in people; in leadership and in innovation; We are the Transformation. Dr. Kamal K. Sharma Vice Chairman Lupin Limited Confidence in people; in leadership and in innovation; We are the Transformation 11 12 Powering Up Chief Executive Officer and Managing Director’s Letter Dear Shareholders, FY 2016 was a very important year for Lupin and marked the beginning of a new era in Lupin’s evolution as a global pharmaceutical powerhouse. A transformational year, which saw us accelerate our efforts to increase depth and expand our presence in key markets such as US, India and Japan thus adding to our leadership credentials. It was a tough year for the Industry, but record approvals and significant launches enabled Lupin to deliver strong operational performance, countering a volatile economic environment, price erosion, customer consolidation and price cuts and controls. Lupin’s Net Sales grew to ` 137,016 million; EBITDA stood at ` 39,412 million while our Net Profits were ` 22,707 million during FY 2016. The Company has delivered a Compounded Annual Growth Rate (CAGR) of 19% in Net Sales, 27% in EBITDA and 21% in Net Profits for the last 5 years. Lupin is today the 7th and the 9th largest generic pharmaceutical company by market capitalization and sales globally (Bloomberg, FY 2016). The Company is also the 5th largest pharmaceutical player in the US (by prescriptions, IMS Health); the 3rd largest Indian pharmaceutical company by revenues and the 9th largest generic pharmaceutical company in Japan. FY 2016 saw the Company make its highest investment in research so far, as we focused on building a pipeline in niche high-barrier segments such as Inhalation, Biosimilars and Complex Injectables. Lupin also added and operationalized 3 new manufacturing facilities (2 Formulations and 1 API facility) in India to meet future market demand. Importantly, we completed the acquisition of US based Gavis Pharmaceuticals
Load more

Recommended publications
  • Pharma Limited. Lupin Limited, Lupin
    Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 1 of 17 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND SHIRE PHARMACEUTICAL DEVELOPMENT INC., SHIRE DEVELOPMENT LLC, COSMO TECHNOLOGIES LIMITED, and NOGRA Civil Action No. PHARMA LIMITED. Plaintiffs, v. LUPIN LIMITED, LUPIN PHARMACEUTICALS INC., LUPIN INC., and LUPIN ATLANTIS HOLDINGS SA Defendants. COMPLAINT Plaintiffs Shire Pharmaceutical Development Inc., Shire Development LLC (collectively, "Shire"), Cosmo Technologies Limited ("Cosmo"), and Nogra Pharma Limited ("Nogra") (collectively, "Plaintiffs") by their undersigned attomeys, for their Complaint against defendants Lupin Limited ("Lupin Ltd."), Lupin Pharmaceuticals Inc. ("LPI"), Lupin Inc. ("Lupin Inc."), and Lupin Atlantis Holdings SA ("Lupin Atlantis") (collectively "Lupin" or "Defendants") herein, allege as follows: NATURE OF THE ACTION l. This is a civil action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent No.6,773,720 ("the '720 patent" or "the patent-in-suit"), attached hereto as Exhibit A. Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 2 of 17 THE PARTIES 2. Plaintiff Shire Pharmaceutical Development Inc. is a corporation organized and existing under the laws of the state of Maryland, having its principal place of business at 1200 Morris Drive, Wayne, PA 19087. 3. Plaintiff Shire Development LLC is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at735 Chesterbrook Boulevard and 1200 Monis Drive, Wayne, Pennsylvania 19087. 4. Plaintiff Cosmo is a company organized and existing under the laws of Ireland, having its principal place of business at The Connolly Building, 42-43 Amiens Street, Dublin l, Ireland.
    [Show full text]
  • Arjuna Award Winners from All Categories Year Category Name
    OLYMPIC DREAM INDIA Arjuna Award Winners from All Categories Year Category Name 2016 Boxing Shiva Thapa 2016 Billiards & Sourav Kothari Snooker 2016 Athletics Lalita Shivaji Babar 2016 Cricket Ajinkya Rahane 2015 Gymnastics Dipa Karmakar 2015 Kabaddi Abhilasha Shashikant Mhatre 2015 Rowing Sawarn Singh 2015 Weightlifting Sathish Kumar Sivalingam 2015 Boxing Mandeep Jangra 2015 Athletics Machettira Raju Poovamma 2015 Archery Naib Subedar Sandeep Kumar 2015 Shooting Jitu Rai 2015 Kabaddi Manjeet Chhillar 2015 Cricket Rohit Sharma 2015 Wrestling Bajrang Kumar 1 OLYMPIC DREAM INDIA 2015 Wrestling Babita Kumari 2015 Wushu Yumnam Sanathoi Devi 2015 Swimming Sharath M. Gayakwad (Paralympic Swimming) 2015 RollerSkating Anup Kumar Yama 2015 Badminton Kidambi Srikanth Nammalwar 2015 Hockey Parattu Raveendran Sreejesh 2014 Weightlifting Renubala Chanu 2014 Archery Abhishek Verma 2014 Athletics Tintu Luka 2014 Cricket Ravichandran Ashwin 2014 Kabaddi Mamta Pujari 2014 Shooting Heena Sidhu 2014 Rowing Saji Thomas 2014 Wrestling Sunil Kumar Rana 2014 Volleyball Tom Joseph 2014 Squash Anaka Alankamony 2014 Basketball Geetu Anna Jose 2 OLYMPIC DREAM INDIA 2014 Badminton Valiyaveetil Diju 2013 Hockey Saba Anjum 2013 Golf Gaganjeet Bhullar 2013 Athletics Ranjith Maheshwari (Athlete) 2013 Cricket Virat Kohli 2013 Archery Chekrovolu Swuro 2013 Badminton Pusarla Venkata Sindhu 2013 Billiards & Rupesh Shah Snooker 2013 Boxing Kavita Chahal 2013 Chess Abhijeet Gupta 2013 Shooting Rajkumari Rathore 2013 Squash Joshna Chinappa 2013 Wrestling Neha Rathi 2013 Wrestling Dharmender Dalal 2013 Athletics Amit Kumar Saroha 2012 Wrestling Narsingh Yadav 2012 Cricket Yuvraj Singh 3 OLYMPIC DREAM INDIA 2012 Swimming Sandeep Sejwal 2012 Billiards & Aditya S. Mehta Snooker 2012 Judo Yashpal Solanki 2012 Boxing Vikas Krishan 2012 Badminton Ashwini Ponnappa 2012 Polo Samir Suhag 2012 Badminton Parupalli Kashyap 2012 Hockey Sardar Singh 2012 Kabaddi Anup Kumar 2012 Wrestling Rajinder Kumar 2012 Wrestling Geeta Phogat 2012 Wushu M.
    [Show full text]
  • S.No. NAME of APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMI
    AEO T2 CERTIFIED ENTITIES S.No. NAME OF APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMITED 0588085481 4 NIPPON PAINT INDIA PRIVATE LIMITED 0505090619 5 DANFOSS INDIA PRIVATE LIMITED 0598045848 6 HONDA CARS INDIA LIMITED 0595049338 7 ANUPAM COLOURS PRIVATE LIMITED 0301012610 8 BOSCH AUTOMOTIVE ELECTRONICS INDIA PRIVATE LIMITED 0708022308 9 BOSCH LIMITED 0788000314 10 VELANKANI ELECTRONICS PRIVATE LIMITED 0715009729 11 FERRERO INDIA PRIVATE LIMITED 0707029953 12 SIEMENS LIMITED 0388070005 13 ENCUBE ETHICALS PRIVATE LIMITED 0396057993 14 NESTLE INDIA LIMITED 0588000531 15 3M INDIA LIMITED 0793012112 16 BIOLOGICAL E. LIMITED 0988000229 17 TOYOTA KIRLOSKAR MOTOR PRIVATE LIMITED 0797012451 18 MICROMAX INFORMATICS LIMITED 0503028665 19 3M ELECTRO & COMMUNICATION INDIA PRIVATE LIMITED 0493021329 20 DELL INTERNATIONAL SERVICES INDIA PRIVATE LIMITED 5196000691 21 EMBARKATION HEADQUARTERS 0307061281 22 USHODAYA ENTERPRISES PRIVATE LIMITED 0988001071 23 SAMSUNG INDIA ELECTRONICS PRIVATE LIMITED 0595032818 24 LENOVO INDIA PRIVATE LIMITED 0705001091 25 KUNDAN CARE PRODUCTS LIMTED 0504074008 26 INA BEARINGS INDIA PRIVATE LIMITED 3197032462 27 SCHNEIDER ELECTRIC INDIA PRIVATE LIMITED 0595007317 28 ORDNANCE FACTORY BOARD MUMBAI OFFICE MINISTRY OF DEFENCE 0307084434 29 JABIL CIRCUIT INDIA PRIVATE LIMITED 0302051139 30 KASTURI AND SONS LIMITED 0488007542 31 POPPYS KNITWEAR PRIVATE LIMITED 0488013011 32 ASTRA MICROWAVE PRODUCTS LIMITED 0991002300 33 CATERPILLAR INDIA PRIVATE LIMITED 0400023067
    [Show full text]
  • Lupin Limited: Rating Removed from Watch with Developing Implications
    November 20, 2019 Lupin Limited: Rating removed from watch with developing implications Summary of rating action Instrument* Previous Rated Amount Current Rated Amount Rating Action (Rs. crore) (Rs. crore) Short-term Fund-based 1,100.0 1,100.0 [ICRA]A1+, removed from Limits rating watch with developing implications Short-term Non-fund 400.0 400.0 [ICRA]A1+; removed from Based Limits rating watch with developing implications Total 1,500.0 1,500.0 *Instrument details are provided in Annexure-1 Material event Lupin Limited, on November 11, 2019, announced that it has approved the divestment of its entire equity interest (representing 99.82% of the issued and paid-up capital) of Kyowa Pharmaceutical Industry Co. Ltd (Kyowa) by way of sale of shares to Plutus Limited (an entity affiliated with Unison Capital partners) at an enterprise value (EV) of JPY 57,361 million (Rs.3702 crore), subject to necessary approvals including Japan Fair Trade Commission and shareholders of the company. The proposed transaction is an all cash-transaction, valued at EV/sales of 2 times and will result in post- tax net cash inflow of ~JPY 32,596 million (Rs. 2,104 crore). The transaction is expected to be concluded within FY2020. Impact of material event ICRA has a short-term rating of [ICRA]A1+ (pronounced ICRA A one plus) assigned to the Rs. 1,100-crore short-term fund- based limits and Rs. 400-crore short-term non-fund based limits. The rating has been removed from watch with developing implications. Rationale The removal of the rating watch factors in the expected strengthening of the credit profile of Lupin Limited, following the divestment of Kyowa (which accounted for 10.6% of consolidated operating income (OI) and 9.1% of OPBDITA of Lupin in FY2019), along with receipt of post-tax cash proceeds of JPY 32,596 million (Rs.2,104 crore).
    [Show full text]
  • United States Court of Appeals for the Federal Circuit ______
    Case: 16-1973 Document: 3-2 Page: 1 Filed: 07/20/2017 NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff-Appellant v. ZYDUS PHARMACEUTICALS USA, INC., CADILA HEALTHCARE, LIMITED, MYLAN INC., MYLAN PHARMACEUTICALS INC., TORRENT PHARMACEUTICALS LIMITED, TORRENT PHARMA INC., HETERO LABS LIMITED, AJANTA PHARMA LIMITED, AJANTA PHARMA USA INC., AUROBINDO PHARMA LTD., INTAS PHARMACEUTICALS LIMITED, ACCORD HEALTHCARE, INC., AUROBINDO PHARMA USA INC., AUROLIFE PHARMA LLC, LUPIN LIMITED, LUPIN ATLANTIS HOLDINGS S.A., LUPIN PHARMACEUTICALS, INC., ALEMBIC PHARMACEUTICALS LIMITED, AMNEAL PHARMACEUTICALS, LLC, AMNEAL PHARMACEUTICALS INDIA PVT. LTD., Defendants-Appellees ______________________ 2016-1962, 2016-1963, 2016-1964, 2016-1966, 2016-1968, 2016-1970, 2016-1971, 2016-1972, 2016-1973, 2016-1974, 2016-1975, 2016-1978 ______________________ Appeals from the United States District Court for the District of New Jersey in Nos. 1:14-cv-03168-JBS-KMW, Case: 16-1973 Document: 3-2 Page: 2 Filed: 07/20/2017 1:14-cv-04508-JBS-KMW, 1:14-cv-04671-JBS-KMW, 1:14- cv-05876-JBS-KMW, 1:14-cv-06158-JBS-KMW, 1:14-cv- 06890-JBS-KMW, 1:14-cv-07105-JBS-KMW, 1:14-cv- 07252-JBS-KMW, 1:14-cv-07405-JBS-KMW, 1:14-cv- 08074-JBS-KMW, 1:14-cv-08077-JBS-KMW, 1:15-cv- 01585-JBS-KMW, Chief Judge Jerome B. Simandle. ______________________ JUDGMENT ______________________ PAUL WILLIAM BROWNING, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC, argued for plaintiff-appellant. Also represented by JAMES B. MONROE, CHARLES THOMAS COLLINS-CHASE, ERIC JAY FUES, ANDREA DENISE MAIN; JEFFREY ANDREW FREEMAN, Atlanta, GA.
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • Revision in Market Lot of Derivative Contracts on Individual Stocks
    Department : FUTURES & OPTIONS Download Ref No: NSE/FAOP/45895 Date : September 30, 2020 Circular Ref. No: 87/2020 All Members, Revision in Market Lot of Derivative Contracts on Individual Stocks In pursuance of SEBI guidelines for periodic revision of lot sizes for derivatives contracts specified in the SEBI circular CIR/MRD/DP/14/2015 dated July 13, 2015, the market lots of derivatives contracts shall be revised as follows: Sr. Underlying whose Derivative Count of Annexure No Effective date contract size shall be Underlying Number October 30, 2020 (for Nov 1 Revised Downwards 15 1 2020 & later expiries) 2 Revised Upwards 12 October 30, 2020 (for Jan 2 2021 & later expiries) 3 Unchanged 108 - 3 Revised Downwards but new October 30, 2020 (for Jan 4 lot size is not a multiple of old 1 4 2021 & later expiries) lot size To avoid operational complexities, in case of Annexure 2 and 4 above, following will be applicable: 1. Only the far month contract i.e. January 2021 expiry contracts will be revised for market lots. Contracts with maturity of November 2020 and December 2020 would continue to have the existing market lots. All subsequent contracts (i.e. January 2021 expiry and beyond) will have revised market lots. 2. The day spread order book will not be available for the combination contract of Dec 2020 – Jan 2021 expiry. For the purpose of the computation, the average of the closing price of the underlying has been taken for one month period of September 1st – September 30th 2020. This circular shall come into effect from October 30, 2020.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2019 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (Rs.) Abhay Kumar Chief Talent Officer Master of Arts / 17 53 3/10/2016 Piramal Pharma 15,034,298.00 Srivastava Master of Personal Solutions Management Ademola Olukayode Head - Quality Doctorate / MPH / B. 17 48 20/6/2018 US FOOD AND DRUG 17,982,961.00 Daramola Compliance & Tech. ADMINISTRATION Sustainability (US FDA) Ajay Luharuka Head Finance - IPD, B.com,MMS,CFA 23 46 11/7/1996 NIIT Limited 11,922,994.00 API, Specialty & Global Respi Aliakbar Rangwala Senior Business Head M. Sc. / B. Sc. 19 42 19/1/2009 NA 10,677,779.00 - Chronic & Emerging - India Business Alpana Vartak Head - Talent MBA (HR) / B. Sc. 15 41 8/1/2018 Coco - Cola 10,312,782.00 Acquisition Company Anil Kartha Site Head - Bsc, Bpharm 28 56 27/5/1991 Vysali 12,525,338.00 Patalganga - Pharmaceuticals Formulations Anindya Kumar Shee Head - Organization B. Tech. / MBA 18 48 14/1/2016 Reliance Industries 11,084,298.00 Development Ltd.
    [Show full text]
  • DR REDDYS LABORATORIES LTD Form 20-F Filed 2020-06-15
    SECURITIES AND EXCHANGE COMMISSION FORM 20-F Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Filing Date: 2020-06-15 | Period of Report: 2020-03-31 SEC Accession No. 0001575872-20-000145 (HTML Version on secdatabase.com) FILER DR REDDYS LABORATORIES LTD Mailing Address Business Address 8-2-337, ROAD NO.3 8-2-337, ROAD NO.3 CIK:1135951| IRS No.: 000000000 | Fiscal Year End: 0331 BANJARA HILLS BANJARA HILLS Type: 20-F | Act: 34 | File No.: 001-15182 | Film No.: 20963158 HYDERABAD K7 500-034 HYDERABAD K7 500-034 SIC: 2834 Pharmaceutical preparations 91 40 49002900 Copyright © 2020 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT ¨ OF 1934 OR þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ¨ 1934 Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No.
    [Show full text]
  • List of Nodal Officer
    List of Nodal Officer Designa S.No tion of Phone (With Company Name EMAIL_ID_COMPANY FIRST_NAME MIDDLE_NAME LAST_NAME Line I Line II CITY PIN Code EMAIL_ID . Nodal STD/ISD) Officer 1 VIPUL LIMITED [email protected] PUNIT BERIWALA DIRT Vipul TechSquare, Golf Course Road, Sector-43, Gurgaon 122009 01244065500 [email protected] 2 ORIENT PAPER AND INDUSTRIES LTD. [email protected] RAM PRASAD DUTTA CSEC BIRLA BUILDING, 9TH FLOOR, 9/1, R. N. MUKHERJEE ROAD KOLKATA 700001 03340823700 [email protected] COAL INDIA LIMITED, Coal Bhawan, AF-III, 3rd Floor CORE-2,Action Area-1A, 3 COAL INDIA LTD GOVT OF INDIA UNDERTAKING [email protected] MAHADEVAN VISWANATHAN CSEC Rajarhat, Kolkata 700156 03323246526 [email protected] PREMISES NO-04-MAR New Town, MULTI COMMODITY EXCHANGE OF INDIA Exchange Square, Suren Road, 4 [email protected] AJAY PURI CSEC Multi Commodity Exchange of India Limited Mumbai 400093 0226718888 [email protected] LIMITED Chakala, Andheri (East), 5 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 6 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 7 NECTAR LIFE SCIENCES LIMITED [email protected] SUKRITI SAINI CSEC NECTAR LIFESCIENCES LIMITED SCO 38-39, SECTOR 9-D CHANDIGARH 160009 01723047759 [email protected] 8 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 9 SMIFS CAPITAL MARKETS LTD.
    [Show full text]
  • Dr. Reddy's Laboratories . Company  Dr
    BY SHIVAM RAJPUT Dr. Reddy's Laboratories . Company Dr. Reddy's Laboratories Ltd, is a pharmaceutical company based in Hyderabad, Andhra Pradesh, India. Headquarters: HYDERABAD, india Founder: Kallam Anji Reddy Founded: 1984 Company Profile The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed. They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". Reddy's sold the joint venture to the Kremlin-friendly Sistema group. In 1993, Reddy's entered into a joint venture in the Middle East and created two formulation units there and in Russia. Reddy's exported bulk drugs to these formulation units, which then converted them into finished products. In 1994, Reddy's started targeting the US generic market by building state of art manufacturing facility. In March 2002 Dr Reddy’s acquired BHM Laboratories ,Beverley, and its wholly owned subsidiary meridian health care, EURO 14.81 million. Recently Dr. Reddy’s entered into R & D and Commercialization agreement with Argenta Discovery Ltd, for the treatment of COPD. In march 2006 Dr.reddy’s acquired Betapharm arzneimittel GmbH from 3i for euro 480 million. Betapharm employs more than 350 personnel and its turnover amounts to Euro 186 million . It commands a share of 3.5 % in the German pharmaceutical market. In 2006 – 2007, Dr Reddy’s generated a revenue of EUR 80.5 million from Europe , which accounted for 18% of the company’s total revenue.
    [Show full text]
  • Internal Audit Amidst Change Q1 2013
    Trends and Moves CFO Newsletter Internal Audit amidst change Q1 2013 Demands on today’s finance and risk functions have increased because of the challenging macroeconomic environment and changing regulatory requirements. Multinational companies are looking to raise the status and importance of their corporate governance systems, as their Boards are under particular pressure from the shareholders. Internal Audit, as a core finance function, is currently experiencing several specific trends. Due to the successful implementation of Sarbanes-Oxley and the corresponding tightening of the corporate control environment, more is expected of internal audit than simply “checking the box”. The audit function is now about providing a strategic “risk-centric” approach to audit, being proactive in identifying risk and changes to the business as well as proposing control strategies to meet all regulatory demand. Audit leaders are expected to be able to partner closely with the business leaders, rather than acting as a “policeman”. As companies are looking for audit leaders with strong commercial acumen and influencing skills, we have witnessed an open mindedness towards recruiting non-career audit finance individuals into senior audit positions. Companies are increasingly promoting controllers, divisional finance directors and senior operations professionals with solid business and leadership skills to lead the audit functions. This pattern has been witnessed particularly in Asia Pacific, where the Audit as a function is not as mature as those in the U.S. and Europe. PEOPLE MOVES Global CFO Moves Accenture | Accenture has promoted David Rowland, Senior Vice President- Finance to CFO effective in August, following Pamela Craig’s retirement. He has been with Accenture since 1983.
    [Show full text]